{"groups":[{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"FG000","title":"Clo/BU4 20mg/m^2"},{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"FG001","title":"Clo/BU4 30mg/m^2"},{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"FG002","title":"Clo/BU4 40mg/m^2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients with relapsed or refractory hematologic malignancies not in remission received unmanipulated HSCT with CloBu4 conditioning from October 2007 to November 2009 at the University of Michigan. Patients received a clofarabine dose of 20mg/m\\^2, 30 mg/m\\^2 or 40 mg/m\\^2."}